Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL.

Datos básicos

Protocolo:: DSC/08/2357/32
EUDRACT:
NCT:
Centro:: HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Año de incio:: 2024
Año de finalización:

ENSAYO CLÍNICO

Documentos

No hay documentos

Participantes

Elvira Mora Castera

Investigador Principal

Grupos

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos

Financiadores - Promotores

ITALFARMACO S.P.A.

Resultados del Ensayo Clínico

Publicaciones en Revistas 11

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Castano-Diez, Sandra; (...); Diaz-Beya, Marina

Article. 10.1182/bloodadvances.2024013648. 2025

Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

del Pozo, Victoria; (...); Rua-Figueroa, Inigo

Review. 10.3389/fimmu.2023.1310211. 2024

Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain.

Giraldo P; (...); Morales-Conejo M

Article. 10.1016/j.medcli.2024.06.006. 2024

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Pastor-Galan, Irene; (...); Hernandez-Boluda, Juan Carlos

Article. 10.1038/s41375-024-02389-2. 2024

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

Mosquera-Orgueira, Adrian; (...); Hernandez-Boluda, Juan C.

Letter. 10.1002/hem3.60. 2024

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin

Article. 10.1007/s00277-024-05906-6. 2024

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Goetze, Katharina S. S.; (...); Platzbecker, Uwe

Meeting Abstract. 2024

Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.

Serrano-Gonzalo, Irene; (...); Giraldo, Pilar

Article. 10.1186/s13023-023-02939-4. 2023

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.

Crisà E; (...); Santini V

Article. 10.1038/s41375-024-02360-1. 2024

Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.

Mosquera Orgueira, Adrian; (...); Valcarcel, David

Article. 10.1111/bjh.19341. 2024